English
简体中文
Total: £ 56.28
Published Date: 2025-04-14 | Pages: 74 | Tables: 77 | New Technology
The global market for Antibody-oligonucleotide Conjugates (AOCs) was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ 1428 million by 2031, growing at a CAGR of 18.2% during the forecast period.
AOCs (Antibody-Oligonucleotide Conjugates) consist of three main components: a carrier (antibody), a linker, and a small nucleic acid. They allow for targeted delivery, combining the antibody’s ability to bind to specific cells with the gene-silencing capability of small nucleic acids, addressing the delivery challenges faced by conventional small nucleic acid drugs.
The development of Antibody-Oligonucleotide Conjugates (AOCs) aims to address the inherent limitations of small nucleic acids, such as poor serum stability, low membrane permeability, and lack of tissue selectivity. AOCs combine the longer half-life and precise targeting capabilities of antibodies with the gene-silencing power of small nucleic acids, achieving high-precision selectivity and effective delivery to target cells.
The global Antibody-oligonucleotide Conjugates (AOCs) market is experiencing explosive growth, with the core driving force coming from clinical breakthroughs in rare diseases (such as Duchenne muscular dystrophy and myotonic dystrophy) and innovative needs for targeted tumor therapy. Leading companies Avidity Biosciences (AOC 1001 clinical phase II) and Dyne Therapeutics (FORCE™ platform) are leading the race. On the technical side, pH-sensitive linkers optimize oligonucleotide release and bispecific antibody design improves tissue penetration, but low lysosomal escape efficiency (<10%) and high large-scale production costs (single dose exceeds US$50,000) are still the main bottlenecks. Regionally, North America accounts for more than 60% of the market share thanks to FDA accelerated approval and biotechnology clusters, while Asia Pacific relies on CDMO companies such as WuXi Biologics to enter the production link. In the next 3-5 years, with more than 20 AOC pipelines entering the clinic (indications expanding to ophthalmology and CNS) and AI-driven conjugation design (such as generative AI-optimized antibody-oligonucleotide pairing) being implemented, this field is expected to replicate the successful path of ADC drugs and become the next tens of billions of dollars market for precision medicine.
This report aims to provide a comprehensive presentation of the global market for Antibody-oligonucleotide Conjugates (AOCs), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibody-oligonucleotide Conjugates (AOCs).
The Antibody-oligonucleotide Conjugates (AOCs) market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Antibody-oligonucleotide Conjugates (AOCs) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antibody-oligonucleotide Conjugates (AOCs) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Avidity Biosciences
Dyne Therapeutics
Tallac Therapeutics
Creative Biolabs
Abzena
BOCSCI Inc.
Wuxi AppTec
Lonza
Leinco
Segment by Type
Chemical Coupling
Enzymatic Coupling
Segment by Application
Pharmaceuticals
Scientific Research
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antibody-oligonucleotide Conjugates (AOCs) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Chemical Coupling
1.2.3 Enzymatic Coupling
1.3 Market by Application
1.3.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Pharmaceuticals
1.3.3 Scientific Research
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Perspective (2020-2031)
2.2 Global Antibody-oligonucleotide Conjugates (AOCs) Growth Trends by Region
2.2.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Antibody-oligonucleotide Conjugates (AOCs) Historic Market Size by Region (2020-2025)
2.2.3 Antibody-oligonucleotide Conjugates (AOCs) Forecasted Market Size by Region (2026-2031)
2.3 Antibody-oligonucleotide Conjugates (AOCs) Market Dynamics
2.3.1 Antibody-oligonucleotide Conjugates (AOCs) Industry Trends
2.3.2 Antibody-oligonucleotide Conjugates (AOCs) Market Drivers
2.3.3 Antibody-oligonucleotide Conjugates (AOCs) Market Challenges
2.3.4 Antibody-oligonucleotide Conjugates (AOCs) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antibody-oligonucleotide Conjugates (AOCs) Players by Revenue
3.1.1 Global Top Antibody-oligonucleotide Conjugates (AOCs) Players by Revenue (2020-2025)
3.1.2 Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Players (2020-2025)
3.2 Global Top Antibody-oligonucleotide Conjugates (AOCs) Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Antibody-oligonucleotide Conjugates (AOCs) Revenue
3.4 Global Antibody-oligonucleotide Conjugates (AOCs) Market Concentration Ratio
3.4.1 Global Antibody-oligonucleotide Conjugates (AOCs) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antibody-oligonucleotide Conjugates (AOCs) Revenue in 2024
3.5 Global Key Players of Antibody-oligonucleotide Conjugates (AOCs) Head office and Area Served
3.6 Global Key Players of Antibody-oligonucleotide Conjugates (AOCs), Product and Application
3.7 Global Key Players of Antibody-oligonucleotide Conjugates (AOCs), Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Antibody-oligonucleotide Conjugates (AOCs) Breakdown Data by Type
4.1 Global Antibody-oligonucleotide Conjugates (AOCs) Historic Market Size by Type (2020-2025)
4.2 Global Antibody-oligonucleotide Conjugates (AOCs) Forecasted Market Size by Type (2026-2031)
5 Antibody-oligonucleotide Conjugates (AOCs) Breakdown Data by Application
5.1 Global Antibody-oligonucleotide Conjugates (AOCs) Historic Market Size by Application (2020-2025)
5.2 Global Antibody-oligonucleotide Conjugates (AOCs) Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size (2020-2031)
6.2 North America Antibody-oligonucleotide Conjugates (AOCs) Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2020-2025)
6.4 North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size (2020-2031)
7.2 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2020-2025)
7.4 Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Antibody-oligonucleotide Conjugates (AOCs) Market Size (2020-2031)
8.2 Asia-Pacific Antibody-oligonucleotide Conjugates (AOCs) Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region (2020-2025)
8.4 Asia-Pacific Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size (2020-2031)
9.2 Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2020-2025)
9.4 Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Antibody-oligonucleotide Conjugates (AOCs) Market Size (2020-2031)
10.2 Middle East & Africa Antibody-oligonucleotide Conjugates (AOCs) Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2020-2025)
10.4 Middle East & Africa Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Avidity Biosciences
11.1.1 Avidity Biosciences Company Details
11.1.2 Avidity Biosciences Business Overview
11.1.3 Avidity Biosciences Antibody-oligonucleotide Conjugates (AOCs) Introduction
11.1.4 Avidity Biosciences Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025)
11.1.5 Avidity Biosciences Recent Development
11.2 Dyne Therapeutics
11.2.1 Dyne Therapeutics Company Details
11.2.2 Dyne Therapeutics Business Overview
11.2.3 Dyne Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Introduction
11.2.4 Dyne Therapeutics Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025)
11.2.5 Dyne Therapeutics Recent Development
11.3 Tallac Therapeutics
11.3.1 Tallac Therapeutics Company Details
11.3.2 Tallac Therapeutics Business Overview
11.3.3 Tallac Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Introduction
11.3.4 Tallac Therapeutics Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025)
11.3.5 Tallac Therapeutics Recent Development
11.4 Creative Biolabs
11.4.1 Creative Biolabs Company Details
11.4.2 Creative Biolabs Business Overview
11.4.3 Creative Biolabs Antibody-oligonucleotide Conjugates (AOCs) Introduction
11.4.4 Creative Biolabs Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025)
11.4.5 Creative Biolabs Recent Development
11.5 Abzena
11.5.1 Abzena Company Details
11.5.2 Abzena Business Overview
11.5.3 Abzena Antibody-oligonucleotide Conjugates (AOCs) Introduction
11.5.4 Abzena Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025)
11.5.5 Abzena Recent Development
11.6 BOCSCI Inc.
11.6.1 BOCSCI Inc. Company Details
11.6.2 BOCSCI Inc. Business Overview
11.6.3 BOCSCI Inc. Antibody-oligonucleotide Conjugates (AOCs) Introduction
11.6.4 BOCSCI Inc. Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025)
11.6.5 BOCSCI Inc. Recent Development
11.7 Wuxi AppTec
11.7.1 Wuxi AppTec Company Details
11.7.2 Wuxi AppTec Business Overview
11.7.3 Wuxi AppTec Antibody-oligonucleotide Conjugates (AOCs) Introduction
11.7.4 Wuxi AppTec Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025)
11.7.5 Wuxi AppTec Recent Development
11.8 Lonza
11.8.1 Lonza Company Details
11.8.2 Lonza Business Overview
11.8.3 Lonza Antibody-oligonucleotide Conjugates (AOCs) Introduction
11.8.4 Lonza Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025)
11.8.5 Lonza Recent Development
11.9 Leinco
11.9.1 Leinco Company Details
11.9.2 Leinco Business Overview
11.9.3 Leinco Antibody-oligonucleotide Conjugates (AOCs) Introduction
11.9.4 Leinco Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025)
11.9.5 Leinco Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Chemical Coupling
Table 3. Key Players of Enzymatic Coupling
Table 4. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 5. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region (2020-2025) & (US$ Million)
Table 7. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Region (2020-2025)
Table 8. Global Antibody-oligonucleotide Conjugates (AOCs) Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 9. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Region (2026-2031)
Table 10. Antibody-oligonucleotide Conjugates (AOCs) Market Trends
Table 11. Antibody-oligonucleotide Conjugates (AOCs) Market Drivers
Table 12. Antibody-oligonucleotide Conjugates (AOCs) Market Challenges
Table 13. Antibody-oligonucleotide Conjugates (AOCs) Market Restraints
Table 14. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue by Players (2020-2025) & (US$ Million)
Table 15. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Players (2020-2025)
Table 16. Global Top Antibody-oligonucleotide Conjugates (AOCs) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody-oligonucleotide Conjugates (AOCs) as of 2024)
Table 17. Ranking of Global Top Antibody-oligonucleotide Conjugates (AOCs) Companies by Revenue (US$ Million) in 2024
Table 18. Global 5 Largest Players Market Share by Antibody-oligonucleotide Conjugates (AOCs) Revenue (CR5 and HHI) & (2020-2025)
Table 19. Global Key Players of Antibody-oligonucleotide Conjugates (AOCs), Headquarters and Area Served
Table 20. Global Key Players of Antibody-oligonucleotide Conjugates (AOCs), Product and Application
Table 21. Global Key Players of Antibody-oligonucleotide Conjugates (AOCs), Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Type (2020-2025) & (US$ Million)
Table 24. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Type (2020-2025)
Table 25. Global Antibody-oligonucleotide Conjugates (AOCs) Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 26. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Type (2026-2031)
Table 27. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2020-2025) & (US$ Million)
Table 28. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Application (2020-2025)
Table 29. Global Antibody-oligonucleotide Conjugates (AOCs) Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 30. Global Antibody-oligonucleotide Conjugates (AOCs) Revenue Market Share by Application (2026-2031)
Table 31. North America Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 32. North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2020-2025) & (US$ Million)
Table 33. North America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2026-2031) & (US$ Million)
Table 34. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2020-2025) & (US$ Million)
Table 36. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2026-2031) & (US$ Million)
Table 37. Asia-Pacific Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 38. Asia-Pacific Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region (2020-2025) & (US$ Million)
Table 39. Asia-Pacific Antibody-oligonucleotide Conjugates (AOCs) Market Size by Region (2026-2031) & (US$ Million)
Table 40. Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2020-2025) & (US$ Million)
Table 42. Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2026-2031) & (US$ Million)
Table 43. Middle East & Africa Antibody-oligonucleotide Conjugates (AOCs) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Middle East & Africa Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2020-2025) & (US$ Million)
Table 45. Middle East & Africa Antibody-oligonucleotide Conjugates (AOCs) Market Size by Country (2026-2031) & (US$ Million)
Table 46. Avidity Biosciences Company Details
Table 47. Avidity Biosciences Business Overview
Table 48. Avidity Biosciences Antibody-oligonucleotide Conjugates (AOCs) Product
Table 49. Avidity Biosciences Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025) & (US$ Million)
Table 50. Avidity Biosciences Recent Development
Table 51. Dyne Therapeutics Company Details
Table 52. Dyne Therapeutics Business Overview
Table 53. Dyne Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Product
Table 54. Dyne Therapeutics Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025) & (US$ Million)
Table 55. Dyne Therapeutics Recent Development
Table 56. Tallac Therapeutics Company Details
Table 57. Tallac Therapeutics Business Overview
Table 58. Tallac Therapeutics Antibody-oligonucleotide Conjugates (AOCs) Product
Table 59. Tallac Therapeutics Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025) & (US$ Million)
Table 60. Tallac Therapeutics Recent Development
Table 61. Creative Biolabs Company Details
Table 62. Creative Biolabs Business Overview
Table 63. Creative Biolabs Antibody-oligonucleotide Conjugates (AOCs) Product
Table 64. Creative Biolabs Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025) & (US$ Million)
Table 65. Creative Biolabs Recent Development
Table 66. Abzena Company Details
Table 67. Abzena Business Overview
Table 68. Abzena Antibody-oligonucleotide Conjugates (AOCs) Product
Table 69. Abzena Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025) & (US$ Million)
Table 70. Abzena Recent Development
Table 71. BOCSCI Inc. Company Details
Table 72. BOCSCI Inc. Business Overview
Table 73. BOCSCI Inc. Antibody-oligonucleotide Conjugates (AOCs) Product
Table 74. BOCSCI Inc. Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025) & (US$ Million)
Table 75. BOCSCI Inc. Recent Development
Table 76. Wuxi AppTec Company Details
Table 77. Wuxi AppTec Business Overview
Table 78. Wuxi AppTec Antibody-oligonucleotide Conjugates (AOCs) Product
Table 79. Wuxi AppTec Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025) & (US$ Million)
Table 80. Wuxi AppTec Recent Development
Table 81. Lonza Company Details
Table 82. Lonza Business Overview
Table 83. Lonza Antibody-oligonucleotide Conjugates (AOCs) Product
Table 84. Lonza Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025) & (US$ Million)
Table 85. Lonza Recent Development
Table 86. Leinco Company Details
Table 87. Leinco Business Overview
Table 88. Leinco Antibody-oligonucleotide Conjugates (AOCs) Product
Table 89. Leinco Revenue in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025) & (US$ Million)
Table 90. Leinco Recent Development
Table 91. Research Programs/Design for This Report
Table 92. Key Data Information from Secondary Sources
Table 93. Key Data Information from Primary Sources
Table 94. Authors List of This Report
List of Figures
Figure 1. Antibody-oligonucleotide Conjugates (AOCs) Picture
Figure 2. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Type: 2024 VS 2031
Figure 4. Chemical Coupling Features
Figure 5. Enzymatic Coupling Features
Figure 6. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size by Application (2020-2031) & (US$ Million)
Figure 7. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Application: 2024 VS 2031
Figure 8. Pharmaceuticals Case Studies
Figure 9. Scientific Research Case Studies
Figure 10. Antibody-oligonucleotide Conjugates (AOCs) Report Years Considered
Figure 11. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 12. Global Antibody-oligonucleotide Conjugates (AOCs) Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Region: 2024 VS 2031
Figure 14. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Players in 2024
Figure 15. Global Antibody-oligonucleotide Conjugates (AOCs) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 16. The Top 10 and 5 Players Market Share by Antibody-oligonucleotide Conjugates (AOCs) Revenue in 2024
Figure 17. North America Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 18. North America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Country (2020-2031)
Figure 19. United States Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 20. Canada Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe Antibody-oligonucleotide Conjugates (AOCs) Market Share by Country (2020-2031)
Figure 23. Germany Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. France Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. U.K. Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Italy Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Russia Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Nordic Countries Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Asia-Pacific Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific Antibody-oligonucleotide Conjugates (AOCs) Market Share by Region (2020-2031)
Figure 31. China Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Japan Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. South Korea Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Southeast Asia Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. India Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Australia Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America Antibody-oligonucleotide Conjugates (AOCs) Market Share by Country (2020-2031)
Figure 39. Mexico Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Brazil Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Middle East & Africa Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa Antibody-oligonucleotide Conjugates (AOCs) Market Share by Country (2020-2031)
Figure 43. Turkey Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Saudi Arabia Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. UAE Antibody-oligonucleotide Conjugates (AOCs) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Avidity Biosciences Revenue Growth Rate in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025)
Figure 47. Dyne Therapeutics Revenue Growth Rate in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025)
Figure 48. Tallac Therapeutics Revenue Growth Rate in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025)
Figure 49. Creative Biolabs Revenue Growth Rate in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025)
Figure 50. Abzena Revenue Growth Rate in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025)
Figure 51. BOCSCI Inc. Revenue Growth Rate in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025)
Figure 52. Wuxi AppTec Revenue Growth Rate in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025)
Figure 53. Lonza Revenue Growth Rate in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025)
Figure 54. Leinco Revenue Growth Rate in Antibody-oligonucleotide Conjugates (AOCs) Business (2020-2025)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed
